Favicon
Favicon

PRESS RELEASE – Ragon faculty study finds combination of two drugs increases the vulnerability of HIV-1 reservoir cells to the immune system.

Date: February 29, 2024 By:

Ragon faculty Mathias Lichterfeld, MD, PhD, and Xu Yu, MD, have co-authored a paper published in Cell which found evidence that a combination of two drugs increases the vulnerability of HIV-1 reservoir cells to the immune system — which shows promising results in targeting and reducing the HIV-1 reservoir in people living with HIV.

Using samples provided by a Massachusetts General Hospital human clinical trial, the study found combined treatment with the histone deacetylase inhibitor panobinostat and pegylated interferon-a2a increased the immunological vulnerability of HIV-1 reservoir cells.

This treatment was found to transform the pool of HIV-1 reservoir cells by favoring certain types of HIV-1 proviruses over others. Specifically, the study found that the treatment led to an increase in HIV-1 proviruses integrated in specific genes and chromatin regions, while proviruses near certain molecular target sites were actively selected against. This suggests that the treatment can alter the composition of HIV-1 reservoir cells, potentially affecting the persistence of the virus.

More News

Groundbreaking Discovery Uncovers Achilles’ Heel of Malaria Parasite

A collaborative effort between researchers from Uganda, Tanzania, the US, Spain, and Denmark has resolved a longstanding question in malaria research: Do individuals living in regions with continuous malaria transmission develop broadly neutralizing antibodies (BnAbs) against the malaria parasite? The answer is yes.

Press Releases

Ringel Lab Study Reveals Age-Related Decline in Tumor-Fighting T Cells and Its Impact on Cancer Treatment

Researchers at the Ragon Institute of Mass General Brigham, MIT, and Harvard have uncovered critical insights into how aging impairs the immune system’s ability to fight cancer.